Overview
Maximizing Current Therapies and Exploring Future Directions as PARP Inhibitors Take the Stage in Prostate Cancer
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This curriculum features expert commentaries and case discussions that synthesize data around PARP inhibition and its evolving place in the treatment of patients with prostate cancer. Faculty provide practical guidance to apply available and emerging data in real-world decision-making that clinicians are faced with on a daily basis including: interpreting results to inform treatment decisions, biomarker testing, patient selection, and combination therapy. Video modules are also available as downloadable audio podcasts and transcripts.
This activity is intended for medical oncologists, urologists, pathologists, nurse practitioners, physician assistants and APNs who care for patients with prostate cancer.
The purpose of this activity is to provide clinicians with updated information that impacts the care of patients with prostate cancer. The recent approval of two PARP inhibitors for prostate cancer creates treatment options previously not available. This activity will review the latest clinical data on available and emerging PARP inhibitors in advanced prostate cancer offering guidance and perspectives from expert faculty to help clinicians identify eligible patients and integrate PARP inhibitors into their care.
Upon completion of this activity, participants will be able to:
• Outline the scientific rationale and the mechanisms of action of PARP inhibitors (PARPi) for advanced prostate cancer
• Interpret recent PARPi clinical trial findings and the practice-changing impact for optimizing prostate cancer management
• Review the importance of genomic testing to identify patients who will benefit from treatment strategies incorporating PARPi for advanced prostate cancer
• Apply the most recent clinical data on PARPi to inform clinical decision-making and personalize management of advanced prostate cancer
• Outline the scientific rationale and the mechanisms of action of PARP inhibitors (PARPi) for advanced prostate cancer
• Interpret recent PARPi clinical trial findings and the practice-changing impact for optimizing prostate cancer management
• Review the importance of genomic testing to identify patients who will benefit from treatment strategies incorporating PARPi for advanced prostate cancer
• Apply the most recent clinical data on PARPi to inform clinical decision-making and personalize management of advanced prostate cancer
This activity is sponsored by the Academy for Continued Healthcare Learning, in partnership with The University of Texas MD Anderson Cancer Center.
This activity is supported by an educational grant from Pfizer.
Neeraj Agarwal, MD
Professor of Medicine
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, UT
Professor of Medicine
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, UT
Celestia Higano, MD, FACP
Adjunct Professor, Department of Urologic Science
University of British Columbia
Medical Director, Prostate Cancer Supportive Care Program Vancouver Prostate Centre
Vancouver, BC
Daniel Petrylak, MD
Professor of Medicine (Medical Oncology) and of Urology
Co-Director, Signal Transduction Research Program Yale School of Medicine, Yale Cancer Center
New Haven, CT
Patrick G. Pilié, MD
Assistant Professor
GU Medical Oncology
MD Anderson Cancer Center
Houston, TX
Neal Shore, MD, FACS
Medical Director, Carolina Urologic Research Center
Urologist, Atlantic Urology Clinics
Myrtle Beach, SC
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Neeraj Agarwal, MD
Consultant (Occasional): Astellas, Foundation Medicine, Merck
Consultant (Retained): Astellas, AstraZeneca, Bristol Myers Squibb, Bayer, Clovis, EMD Serono, Eisai, Eli Lilly, Exelixis, Foundation Medicine, Genentech, Janssen, Nektar, Novartis, Pfizer, Pharmacyclics, Seattle Genetics
Grant/Research Support Recipient: AstraZeneca, Bristol Myers Squibb, Bavarian Nordic, Bayer, Calithera, Celldex, Clovis, EMD Serono, Eisai, Eli Lilly, Exelixis, Genentech, Glaxo Smith Kline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, Tracon
Celestia Higano, MD, FACP
Consultant (Occasional): Astellas, AstraZeneca, Bayer, Ferring, Genentech, Janssen, Menarini, Myovant, Tolamr
Consultant (Retained): CTI Biopharma
IDMC: Advantagene, Alliance Foundation Trials, Exelixis
Institutional Clinical Research Funding: Hoffman-Laroche, Pfizer, Emergent, Genentech, eFFECTOR Therapeutics, Aptevo, Astellas, AstraZeneca, Clovis, Dendreon
Daniel Petrylak, MD
Consultant (Occasional): Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Incyte, Janssen, Mirati, Monopteros, Pfizer, Pharmacyclics, Roche, Seattle Genetics, Urogen
Grant/Research Support Recipient: Ada Cap (Advanced Accelerator Applications), Agensys Inc., Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Eisai, Eli Lilly, Endocyte, Genentech, Innocrin, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi Aventis, Seattle Genetics
Stock Shareholder (excluding mutual funds): Bellicum
Patrick G. Pilié, MD
Nothing to disclose
Neal Shore, MD, FACS
Consultant (Occasional): Abbvie, Ambry, Amgen, BMS, Boston Scientific, Clovis Oncology, Fergene, Ferring, Foundation Medicine, Janssen, MDX Health, Merck, Myovant, Myriad, Nymox, Pfizer, PlatformQ, Sanofi, Tolmar, Astellas, AstraZeneca, Bayer, Dendreon, Exact Imaging, Invitae
Speaker Bureau: Clovis Oncology, Janssen, Pfizer, Astellas, Bayer
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Talazoparib and emerging combination regimens.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 70% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning designates this enduring material for up to 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
